Atherosclerosis · 2017 · 16 citations · 17 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacovigilanceCardiovascular DiseaseCardiovascular PharmacologyCoronary Artery DiseaseDyslipidemia ManagementDyslipidemia PharmacotherapyLipid-lowering TherapyHigh-density Lipoprotein Cholesterol ManagementHyperlipidemia TreatmentLipid-lowering Drug EfficacyLow-density Lipoprotein Cholesterol LoweringOpen-label TrialsPlacebo ComparatorsSafety Profile CharacterizationStatin Adverse Effects
BACKGROUND AND AIMS: We aimed to assess the effects of cholesteryl ester transfer protein inhibitor anacetrapib added to statin ± other lipid-modifying therapies (LMT) in Japanese patients with dyslipidemia who were not at their LDL-C goal. METHODS: Patients on a stable dose of statin ± other LMT with LDL-C ≥100 mg/dL to <145 mg/dL, ≥120 mg/dL to <165 mg/dL, ≥140 mg/dL or ≥160 mg/dL for patients with a history of coronary heart disease (CHD), high-, moderate- and low-risk patients respectively, were randomized 2:1, stratified by background therapy, to double-blind anacetrapib 100 mg (n = 204) or placebo (n = 103) for 24 weeks, followed by a 28-week open-label extension phase (anacetrapib 100 mg) and a 12-week off-drug safety follow-up phase. The primary endpoint was percent change from baseline in LDL-C (beta-quantification method), as well as the safety profile of anacetrapib at Week 24; HDL-C was a key secondary endpoint. RESULTS: Anacetrapib 100 mg further reduced LDL-C (38.0%), non-HDL-C (35.1%), ApoB (28.7%), and Lp(a) (48.3%) and increased HDL-C (148.9%) and ApoAI (50.7%) versus placebo (p < 0.001 for all). There were no meaningful differences between the groups in the proportion of patients with liver enzymes elevations (2.0% vs. 0%), creatine kinase elevations overall (0.5% vs. 0%) or with muscle symptoms (0.5% vs. 0%), blood pressure, electrolytes or adjudicated cardiovascular events (0.5% vs. 0%). In the open-label period, sustained effects on lipid parameters were observed with anacetrapib and the treatment was generally well tolerated. CONCLUSIONS: Long-term treatment with anacetrapib 100 mg substantially reduced LDL-C, increased HDL-C and was well tolerated in Japanese patients with dyslipidemia (ClinicalTrials.gov number NCT01760460).
17
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Cardiology, Pharmacology +14
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · New England Journal of Medicine · 2012 · 2K citations · Full text
Medicine, Cardiology, Pharmacology +17
Tamio Teramoto, Junichi Sasaki, Shun Ishibashi et al. · Journal of Atherosclerosis and Thrombosis · 2013 · 469 citations · Full text